• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑制 DDX39B 通过使 BRCA1 mRNA 不稳定来使卵巢癌细胞对 DNA 损伤化疗药物敏感。

Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.

机构信息

Department of Radiation Medicine, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Department of Medical Bioinformatics, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

出版信息

Oncogene. 2020 Nov;39(47):7051-7062. doi: 10.1038/s41388-020-01482-x. Epub 2020 Sep 28.

DOI:10.1038/s41388-020-01482-x
PMID:32989256
Abstract

Multiple RNA processing events including transcription, mRNA splicing, and export are delicately coordinated by the TREX complex. As one of the essential subunits, DDX39B couples the splicing and export machineries by recruiting ALYREF onto mRNA. In this study, we further explore the functions of DDX39B in handling damaged DNA, and unexpectedly find that DDX39B facilitates DNA repair by homologous recombination through upregulating BRCA1. Specifically, DDX39B binds to and stabilizes BRCA1 mRNA. DDX39B ensures ssDNA formation and RAD51 accumulation at DSB sites by maintaining BRCA1 levels. Without DDX39B being present, ovarian cancer cells exhibit hypersensitivity to DNA-damaging chemotherapeutic agents like platinum or PARPi. Moreover, DDX39B-deficient mice show embryonic lethality or developmental retardation, highly reminiscent of those lacking BRCA1. High DDX39B expression is correlated with worse survival in ovarian cancer patients. Thus, DDX39B suppression represents a rational approach for enhancing the efficacy of chemotherapy in BRCA1-proficient ovarian cancers.

摘要

多个 RNA 加工事件,包括转录、mRNA 剪接和输出,都被 TREX 复合物精细地协调。作为必需亚基之一,DDX39B 通过将 A LYREF 募集到 mRNA 上来连接剪接和输出机制。在这项研究中,我们进一步探索了 DDX39B 在处理受损 DNA 方面的功能,出乎意料地发现 DDX39B 通过上调 BRCA1 促进同源重组修复。具体而言,DDX39B 与 BRCA1 mRNA 结合并稳定其结构。DDX39B 通过维持 BRCA1 水平来确保 DSB 部位形成单链 DNA 和 RAD51 积累。没有 DDX39B 的存在,卵巢癌细胞对铂类或 PARPi 等 DNA 损伤化疗药物表现出高度敏感性。此外,DDX39B 缺陷小鼠表现出胚胎致死或发育迟缓,与缺乏 BRCA1 的情况非常相似。高 DDX39B 表达与卵巢癌患者的生存预后较差相关。因此,抑制 DDX39B 代表了增强 BRCA1 阳性卵巢癌化疗疗效的合理方法。

相似文献

1
Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.抑制 DDX39B 通过使 BRCA1 mRNA 不稳定来使卵巢癌细胞对 DNA 损伤化疗药物敏感。
Oncogene. 2020 Nov;39(47):7051-7062. doi: 10.1038/s41388-020-01482-x. Epub 2020 Sep 28.
2
BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.BET 蛋白调控同源重组介导的 DNA 修复:BRCA 样特征及其对癌症治疗的影响。
Int J Cancer. 2019 Feb 15;144(4):755-766. doi: 10.1002/ijc.31898. Epub 2018 Dec 4.
3
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.Shieldin 复合物促进 DNA 末端连接,并在 BRCA1 缺失细胞中对抗同源重组。
Nat Cell Biol. 2018 Aug;20(8):954-965. doi: 10.1038/s41556-018-0140-1. Epub 2018 Jul 18.
4
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.突变型 BRCA1 蛋白的稳定导致聚腺苷二磷酸核糖聚合酶抑制剂和铂类耐药。
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6. doi: 10.1073/pnas.1305170110. Epub 2013 Oct 1.
5
LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.LCK 在化疗耐药性卵巢癌的细胞核中稳定 RAD51 和 BRCA1 来促进 DNA 损伤修复。
J Ovarian Res. 2023 Jun 27;16(1):122. doi: 10.1186/s13048-023-01194-2.
6
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.BET 抑制剂 INCB054329 降低卵巢癌细胞中同源重组效率并增强 PARP 抑制剂的活性。
Gynecol Oncol. 2018 Jun;149(3):575-584. doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20.
7
BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.BRCA1/2 信号通路与乳腺癌和卵巢癌同源重组缺陷
Future Oncol. 2021 Jul;17(21):2817-2830. doi: 10.2217/fon-2021-0072. Epub 2021 Jun 1.
8
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.聚腺苷二磷酸核糖聚合酶(PARP)与 ATR 抑制联合克服卵巢癌模型中的 PARP 抑制剂和铂类耐药性。
Nat Commun. 2020 Jul 24;11(1):3726. doi: 10.1038/s41467-020-17127-2.
9
Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?携带BRCA1和BRCA2基因突变的卵巢癌患者的化疗:相同还是不同?
Am Soc Clin Oncol Educ Book. 2015:114-21. doi: 10.14694/EdBook_AM.2015.35.114.
10
Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51.抑制 LSD1 通过下调 BRCA1/2 和 RAD51 增强同源重组修复功能的卵巢癌细胞对 PARP 抑制剂的敏感性。
Nat Commun. 2023 Nov 16;14(1):7430. doi: 10.1038/s41467-023-42850-x.

引用本文的文献

1
Engineered exosomes: a promising design platform for overcoming cancer therapy resistance.工程化外泌体:一种克服癌症治疗耐药性的有前景的设计平台。
Front Cell Dev Biol. 2025 Aug 6;13:1608480. doi: 10.3389/fcell.2025.1608480. eCollection 2025.
2
Addressing the mean-variance relationship in spatially resolved transcriptomics data with spoon.使用Spoon解决空间分辨转录组学数据中的均值-方差关系。
Biostatistics. 2024 Dec 31;26(1). doi: 10.1093/biostatistics/kxaf012.
3
Exploring the impact of cuproptosis on prostate cancer prognosis RNA methylation regulation based on single cell and bulk RNA sequencing data.

本文引用的文献

1
DNA double-strand break repair-pathway choice in somatic mammalian cells.体细胞核哺乳动物细胞中 DNA 双链断裂修复途径的选择。
Nat Rev Mol Cell Biol. 2019 Nov;20(11):698-714. doi: 10.1038/s41580-019-0152-0. Epub 2019 Jul 1.
2
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells.DYNLL1 与 MRE11 结合以限制 BRCA1 缺陷细胞中的 DNA 末端切除。
Nature. 2018 Nov;563(7732):522-526. doi: 10.1038/s41586-018-0670-5. Epub 2018 Oct 31.
3
mRNAs are sorted for export or degradation before passing through nuclear speckles.
基于单细胞和批量RNA测序数据探索铜死亡对前列腺癌预后的影响及RNA甲基化调控
Front Pharmacol. 2025 Apr 1;16:1573611. doi: 10.3389/fphar.2025.1573611. eCollection 2025.
4
RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic-nuclear shuttling in human triple-negative breast cancer.RNF31通过维持ALYREF在人三阴性乳腺癌中的细胞质-细胞核穿梭诱导紫杉醇耐药。
Clin Transl Med. 2025 Feb;15(2):e70203. doi: 10.1002/ctm2.70203.
5
Addressing the mean-variance relationship in spatially resolved transcriptomics data with .用……处理空间转录组学数据中的均值-方差关系
bioRxiv. 2024 Nov 8:2024.11.04.621867. doi: 10.1101/2024.11.04.621867.
6
ALYREF recruits ELAVL1 to promote colorectal tumorigenesis via facilitating RNA m5C recognition and nuclear export.ALYREF招募ELAVL1,通过促进RNA m5C识别和核输出促进结直肠癌发生。
NPJ Precis Oncol. 2024 Oct 25;8(1):243. doi: 10.1038/s41698-024-00737-0.
7
DDX RNA helicases: key players in cellular homeostasis and innate antiviral immunity.DDX RNA 解旋酶:细胞内稳态和先天抗病毒免疫的关键分子。
J Virol. 2024 Oct 22;98(10):e0004024. doi: 10.1128/jvi.00040-24. Epub 2024 Aug 30.
8
Multifunctional role of DEAD-box helicase 41 in innate immunity, hematopoiesis and disease.DEAD-box 解旋酶 41 在先天免疫、造血和疾病中的多功能作用。
Front Immunol. 2024 Aug 9;15:1451705. doi: 10.3389/fimmu.2024.1451705. eCollection 2024.
9
Circular RNA in cancer.环状 RNA 与癌症。
Nat Rev Cancer. 2024 Sep;24(9):597-613. doi: 10.1038/s41568-024-00721-7. Epub 2024 Jul 29.
10
Critical Cellular Functions and Mechanisms of Action of the RNA Helicase UAP56.UAP56 RNA 解旋酶的关键细胞功能和作用机制。
J Mol Biol. 2024 Jun 15;436(12):168604. doi: 10.1016/j.jmb.2024.168604. Epub 2024 May 8.
mRNA 在通过核斑之前被分拣出来进行输出或降解。
Nucleic Acids Res. 2018 Sep 19;46(16):8404-8416. doi: 10.1093/nar/gky650.
4
A length-dependent evolutionarily conserved pathway controls nuclear export of circular RNAs.一种依赖于长度的进化保守途径控制环状 RNA 的核输出。
Genes Dev. 2018 May 1;32(9-10):639-644. doi: 10.1101/gad.314856.118. Epub 2018 May 17.
5
RNA-splicing factor SART3 regulates translesion DNA synthesis.RNA 剪接因子 SART3 调控跨损伤 DNA 合成。
Nucleic Acids Res. 2018 May 18;46(9):4560-4574. doi: 10.1093/nar/gky220.
6
BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing.BRCA1-BARD1促进RAD51介导的同源DNA配对。
Nature. 2017 Oct 19;550(7676):360-365. doi: 10.1038/nature24060. Epub 2017 Oct 4.
7
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.鲁卡帕利治疗复发铂类敏感型高级别卵巢癌(ARIEL2 研究第 1 部分):一项国际多中心、开放标签、2 期临床试验。
Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.
8
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.尼拉帕利维持治疗铂敏感复发性卵巢癌。
N Engl J Med. 2016 Dec 1;375(22):2154-2164. doi: 10.1056/NEJMoa1611310. Epub 2016 Oct 7.
9
Deciphering the BRCA1 Tumor Suppressor Network.解析BRCA1肿瘤抑制网络。
J Biol Chem. 2015 Jul 17;290(29):17724-17732. doi: 10.1074/jbc.R115.667931. Epub 2015 Jun 5.
10
REV7 counteracts DNA double-strand break resection and affects PARP inhibition.REV7可对抗DNA双链断裂切除并影响聚(ADP-核糖)聚合酶抑制作用。
Nature. 2015 May 28;521(7553):541-544. doi: 10.1038/nature14328. Epub 2015 Mar 23.